The article discusses the biological mechanisms underlying metastasis, a major cause of cancer-related deaths. Metastasis involves the dissemination of cancer cells from primary tumors to distant sites, a complex process involving multiple steps. The epithelial-mesenchymal transition (EMT) is a key program enabling cancer cells to acquire traits that facilitate their spread. EMT is a developmental process normally involved in embryogenesis and tissue repair, but it is hijacked by cancer cells to gain mesenchymal traits and enhance metastatic potential. EMT is associated with increased motility, invasiveness, and ECM degradation. However, EMT is not a binary switch, as cancer cells may retain some epithelial traits while acquiring mesenchymal features. EMT is often triggered by signals from the tumor microenvironment, including TGF-β, Wnts, and interleukins. EMT programs are orchestrated by master transcription factors such as Snail, Slug, Twist, and Zeb1. EMT can lead to the acquisition of tumor-initiating ability, a trait associated with cancer stem cells (CSCs). CSCs are more resistant to therapies and can initiate metastatic colonies. However, not all metastases require EMT, as some may arise from cells that have not undergone EMT. Collective migration of carcinoma cells is another mode of dissemination, often seen in invasive carcinomas. This process involves the coordinated movement of large cell groups, which may involve EMT. However, some studies suggest that EMT may not be essential for all metastases. The role of EMT in metastasis remains a topic of debate, with some studies challenging its essentiality. Circulating tumor cells (CTCs) are cancer cells that have entered the bloodstream and may seed new metastases. CTCs can exist as single cells or clusters and may be protected from immune attack by platelets and other cells. CTCs can be detected in the blood and used for diagnostic purposes, as their presence is associated with metastatic potential. However, the exact role of CTCs in metastasis is still unclear, as the probability of a single CTC initiating a metastasis is low. In transit, CTCs face various challenges, including immune attack by NK cells and physical obstacles in the bloodstream. Interactions with platelets, neutrophils, and endothelial cells can facilitate the survival and extravasation of CTCs. Platelets can protect CTCs from immune elimination and alter intracellular signaling pathways that affect metastatic potential. Neutrophils can also influence CTC behavior, either by inhibiting or promoting metastasis. Extravasation is the process by which CTCs leave the bloodstream and enter distant tissues. This requires the cancer cells to traverse the endothelial wall through transendothelial migration (TEM). Factors such as VEGF, MMPs, and ADAM12 can enhance both intravasation andThe article discusses the biological mechanisms underlying metastasis, a major cause of cancer-related deaths. Metastasis involves the dissemination of cancer cells from primary tumors to distant sites, a complex process involving multiple steps. The epithelial-mesenchymal transition (EMT) is a key program enabling cancer cells to acquire traits that facilitate their spread. EMT is a developmental process normally involved in embryogenesis and tissue repair, but it is hijacked by cancer cells to gain mesenchymal traits and enhance metastatic potential. EMT is associated with increased motility, invasiveness, and ECM degradation. However, EMT is not a binary switch, as cancer cells may retain some epithelial traits while acquiring mesenchymal features. EMT is often triggered by signals from the tumor microenvironment, including TGF-β, Wnts, and interleukins. EMT programs are orchestrated by master transcription factors such as Snail, Slug, Twist, and Zeb1. EMT can lead to the acquisition of tumor-initiating ability, a trait associated with cancer stem cells (CSCs). CSCs are more resistant to therapies and can initiate metastatic colonies. However, not all metastases require EMT, as some may arise from cells that have not undergone EMT. Collective migration of carcinoma cells is another mode of dissemination, often seen in invasive carcinomas. This process involves the coordinated movement of large cell groups, which may involve EMT. However, some studies suggest that EMT may not be essential for all metastases. The role of EMT in metastasis remains a topic of debate, with some studies challenging its essentiality. Circulating tumor cells (CTCs) are cancer cells that have entered the bloodstream and may seed new metastases. CTCs can exist as single cells or clusters and may be protected from immune attack by platelets and other cells. CTCs can be detected in the blood and used for diagnostic purposes, as their presence is associated with metastatic potential. However, the exact role of CTCs in metastasis is still unclear, as the probability of a single CTC initiating a metastasis is low. In transit, CTCs face various challenges, including immune attack by NK cells and physical obstacles in the bloodstream. Interactions with platelets, neutrophils, and endothelial cells can facilitate the survival and extravasation of CTCs. Platelets can protect CTCs from immune elimination and alter intracellular signaling pathways that affect metastatic potential. Neutrophils can also influence CTC behavior, either by inhibiting or promoting metastasis. Extravasation is the process by which CTCs leave the bloodstream and enter distant tissues. This requires the cancer cells to traverse the endothelial wall through transendothelial migration (TEM). Factors such as VEGF, MMPs, and ADAM12 can enhance both intravasation and